Suicides increased last year, but attempt survivors at ER decreased: report

Fewer survivors than before were hospitalized after suicide attempts in 2024, raising suspicion that a substantial number were turned away by ERs
The number of suicide deaths in 2024 increased compared to the previous year, but the number of those admitted to the emergency room after attempting suicide actually increased in the same period, leading to suspicion that some of those attempt survivors had been unable to receive medical help.
Local Korean-language daily Kukmin Ilbo on Sunday reported that 23,247 people were admitted to the hospital ER in 2024 after attempting suicide and survived, citing a Ministry of Health and Welfare data submitted to Rep. Kim Nam-hee of the Democratic Party of Korea. This marked a significant decrease from the 30,665 in 2023.
But the number of suicide deaths last year is provisionally tallied at 14,588, which was up from 13,978 in 2023, according to the government-affiliated Korea Foundation for Suicide Prevention's data.
As more suicide deaths is likely to indicate more suicide attempts overall, there has been speculation that people who attempted suicide may have been turned away by hospital emergency rooms, presumably due to lack of staff sparked by the recent medical strike.
In protest of an increase the enrollment for medical schools by the previous administration, doctors across the country have engaged in a mass walkout that resulted in nationwide shortage of medical staff, particularly at major hospitals. This led to spike in reports about emergency patients being sent to another hospital by the staff at hospital emergency rooms, due to the ER being unable to provide necessary medical care.
National Fire Agency data reported in January showed that ambulances carrying emergency patients had been turned away and sent to another hospital 5,657 times in 2024, marking a 34 percent increase from 4,227 in the previous year.
* If you're thinking about self-harm or suicide, contact the Ministry of Health and Welfare's helpline at 109, available 24 hours a day, 7 days a week. Please request a translator for English-language services.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

a day ago

• Korea Herald

[Bio USA] Celltrion deepens global ties, unveils R&D vision at Bio USA

BOSTON — Korean biotech company Celltrion showcased its expanded vision as a next-generation drug developer at Bio USA this week, using the global stage in Boston to deepen ties with international partners and explore cutting-edge biotech collaborations. According to Celltrion on Thursday, the company held more than 150 meetings over the four-day event, engaging in discussions with global pharmaceutical and biotech firms on a wide range of potential collaborations. Over 1,800 visitors stopped by Celltrion's booth during the convention, as announced by the company. Focusing on its core mission of "new drug development" this year, the company concentrated on exploring partnership opportunities to strengthen its pipeline in areas such as antibody-drug conjugates, multispecific antibodies, novel antibody drugs and peptides. The company also held extensive discussions on open innovation initiatives aimed at identifying promising technologies in drug development. Celltrion plans to closely review the meetings from Bio USA to identify potential partners with high growth potential and technical capabilities. In addition, the company said it engaged in wide-ranging talks about expanding its distribution network, receiving collaboration proposals from various companies for drug transportation, storage and other logistical support. Celltrion supplies its biosimilar products through direct sales channels in major global markets. For countries where it relies on indirect sales, the company actively held meetings to strengthen its existing distribution networks. Beyond business meetings, Celltrion also conducted promotional activities throughout the event, such as placing QR-coded brochures throughout its booth to highlight the company's key businesses and major products. Visitors who participated in surveys were offered custom keychains as part of a fun event to drive engagement. 'There was notable interest this year in Celltrion's expansion into the new drug development space,' a Celltrion official said. 'We are committed to securing the best technologies and potential partnerships to advance our pipeline of novel therapeutics. These efforts will reinforce Celltrion's capabilities as it grows into a major global pharmaceutical company.' Celltrion has participated in Bio USA for 16 consecutive years since 2010, continuously seeking global partnerships.

Korea Herald

3 days ago

• Korea Herald

SNU family doctor named as physician to president

Park Sang-min, professor of family medicine at Seoul National University Hospital, has been named the official physician to President Lee Jae-myung, Lee's spokesperson Kang Yu-jung said Thursday. Kang said Park will practice Western medicine as Lee's physician. The presidential office has not unveiled the nomination of a personal doctor dedicated to Korean traditional medicine. The 50-year-old Park, who also heads the Health System Data Science Laboratory of Seoul National University's College of Medicine, has accompanied Lee's recent trip to Canada on the occasion of the Group of Seven summit, according to the presidential office. Seoul added that Park is not a full-time employee of the presidential office and will rather remain employed by Seoul National University Hospital.

Korea Herald

3 days ago

• Korea Herald

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma's Energy-Based Technology

CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform. Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed. This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention. "This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients." Accent Prime combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive treatments for body contouring, skin tightening, and facial rejuvenation. The platform is CE marked and approved for the treatment of various different indications, including facial and body contouring, skin tightening, cellulite reduction, and skin rejuvenation. Widely adopted by leading clinics worldwide, Accent Prime offers flexible, combination-based protocols that support tailored treatment strategies across diverse skin types and body areas—without the need for surgery or downtime. These proprietary ultrasound and radiofrequency technologies have also been clinically validated in other products from Alma's Body Contouring series, such as Alma PrimeX. Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.